Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute, 9731-9732 [2025-02733]
Download as PDF
<![CDATA[
Federal Register / Vol. 90, No. 31 / Tuesday, February 18, 2025 / Notices
ACTION:
Notice.
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 10, 2025, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Shoals Technologies Group,
LLC of Portland, Tennessee.
Supplements to the complaint were
filed on January 24, 2025. The
complaint, as supplemented, alleges
violations of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain photovoltaic trunk bus cable
assemblies and components thereof by
reason of the infringement of certain
claims of U.S. Patent No. 12,015,375
(‘‘the ’375 patent’’) and U.S. Patent No.
12,015,376 (‘‘the ’376 patent’’). The
complaint, as supplemented, further
alleges that an industry in the United
States exists as required by the
applicable Federal Statute.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and a cease and
desist order.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Susan Orndoff, The Office of Docket
Services, U.S. International Trade
Commission, telephone (202) 205–1802.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2024).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
February 11, 2025, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:15 Feb 14, 2025
Jkt 265001
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims
1–12 and 15–24 of the ’375 patent and
claims 1–6, 8–10, 12–16, 19, and 20 of
the ’376 patent, and whether an
industry in the United States exists as
required by subsection (a)(2) of section
337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘photovoltaic trunk bus
cable assemblies for connecting solar
panel arrays to an inverter, which cable
assemblies are called lead assemblies or
trunk buses, and which may also
include one or more drop lines that are
coupled to a feeder cable within said
lead assemblies or trunk buses’’;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is:
Shoals Technologies Group, LLC, 1400
Shoals Way, Portland, TN 37148
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Voltage, LLC, 1450 Raleigh Rd., Ste.
208, Chapel Hill, NC 27517
Ningbo Voltage Smart Production Co.,
No. 201 Bldg. 5 (14) Miaofengshan
Rd., Beilun District, 57020 Ningbo,
China
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The Office of Unfair Import
Investigations will not participate as a
party in this investigation.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainant of the
complaint and the notice of
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
9731
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: February 11, 2025.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2025–02694 Filed 2–14–25; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1495]
Bulk Manufacturer of Controlled
Substances Application: Scottsdale
Research Institute
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Scottsdale Research Institute,
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 21, 2025. Such
persons may also file a written request
for a hearing on the application on or
before April 21, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
SUMMARY:
E:\FR\FM\18FEN1.SGM
18FEN1
9732
Federal Register / Vol. 90, No. 31 / Tuesday, February 18, 2025 / Notices
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 8, 2025,
Scottsdale Research Institute, 12815
North Cave Creek Road, Phoenix,
Arizona 85022, applied to be registered
as a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
Drug
code
Controlled substance
Marihuana Extract .........
Marihuana ......................
Tetrahydrocannabinols ..
I
7350
7360
7370
Schedule
I
I
I
I
The company plans to bulk
manufacture the listed controlled
substances to support clinical trials and
distribution to their customers for
research purposes. No other activities
for these drug codes are authorized for
this registration.
Matthew Strait,
Deputy Assistant Administrator.
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 8, 2025,
Scottsdale Research Institute, 12815
North Cave Creek Road, Phoenix,
Arizona 85022, applied to be registered
as a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
ADDRESSES:
Controlled substance
Ibogaine ...........................
3,4Methylenedioxymethamphetamine.
Drug
code
Schedule
7260
7405
I
I
[FR Doc. 2025–02733 Filed 2–14–25; 8:45 am]
The company plans to bulk
manufacture the listed controlled
substances for internal research and
analytical development purposes. No
other activities for these drug codes are
authorized for this registration.
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Matthew Strait,
Deputy Assistant Administrator.
[Docket No. DEA–1499]
Bulk Manufacturer of Controlled
Substances Application: Scottsdale
Research Institute
[FR Doc. 2025–02739 Filed 2–14–25; 8:45 am]
BILLING CODE P
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Drug Enforcement Administration
Scottsdale Research Institute
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 21, 2025. Such
persons may also file a written request
for a hearing on the application on or
before April 21, 2025.
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
DEPARTMENT OF JUSTICE
VerDate Sep<11>2014
17:15 Feb 14, 2025
Jkt 265001
Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 20, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 20, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on December 5, 2024,
Mylan Pharmaceuticals Inc., 2898
Manufacturers Road, Greensboro, North
Carolina 27406–4600, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
DATES:
Controlled substance
[Docket No. DEA–1493]
Importer of Controlled Substances
Application: Mylan Pharmaceuticals,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Mylan Pharmaceuticals, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Remifentanil .....................
Drug
code
Schedule
I 9739 III
The company plans to import the
listed controlled substance in finished
dosage form for commercial distribution
to its customers. No other activity for
this drug code is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
E:\FR\FM\18FEN1.SGM
18FEN1
]]>Agencies
[Federal Register Volume 90, Number 31 (Tuesday, February 18, 2025)]
[Notices]
[Pages 9731-9732]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-02733]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1495]
Bulk Manufacturer of Controlled Substances Application:
Scottsdale Research Institute
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Scottsdale Research Institute, has applied to be registered as
a bulk manufacturer of basic class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION listed below for further drug
information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
April 21, 2025. Such persons may also file a written request for a
hearing on the application on or before April 21, 2025.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for
[[Page 9732]]
submitting comments. Upon submission of your comment, you will receive
a Comment Tracking Number. Please be aware that submitted comments are
not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number,
your comment has been successfully submitted and there is no need to
resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on January 8, 2025, Scottsdale Research Institute, 12815
North Cave Creek Road, Phoenix, Arizona 85022, applied to be registered
as a bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana Extract...................... 7350 I
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances to support clinical trials and distribution to their
customers for research purposes. No other activities for these drug
codes are authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025-02733 Filed 2-14-25; 8:45 am]
BILLING CODE P
